Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Gennex Laboratories Ltd (GENNEX) is currently trading at 10.68 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products. The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets. It has a vertically integrated business model, enhancing operational efficiencies and product diversification. In 2023, Gennex acquired a 51% share in Deccan Remedies Limited, indicating a strategic move to expand its business scope. The company emphasizes compliance with GMP standards and CGMP guidelines, showcasing its commitment to quality and industry best practices.
Over the past 52 weeks, Gennex Laboratories Ltd has traded between a low of ₹7.05 and a high of ₹17.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gennex Laboratories Ltd has a market capitalization of approximately 252.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gennex Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 252.91 Cr, Gennex Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gennex Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gennex Laboratories Ltd is 13.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
8
Neutral
2
Bullish
4
Bearish
19
Neutral
2
Bullish
25
Bearish
11
Neutral
0
Bullish
21
Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products.
The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets.
It has a vertically integrated business model, enhancing operational efficiencies and product diversification.
In 2023, Gennex acquired a 51% share in Deccan Remedies Limited, indicating a strategic move to expand its business scope.
The company emphasizes compliance with GMP standards and CGMP guidelines, showcasing its commitment to quality and industry best practices.
Pharmaceuticals & Biotechnology
Pharmaceuticals
253 Cr
High Risk
13.7
32.3
0.3
1.2
17.25
7.05
Sales CAGR
Profit CAGR
ROE
ROCE
EGM Notice Publication
Gennex Laboratories published newspaper advertisements of its Extraordinary General Meeting (EGM) notice and e‑voting instructions in Business Standard and Saksham on Apr 21, 2026 for the EGM scheduled on May 12, 2026 and filed the publication under Regulation 47 LODR.
EGM Convening
Gennex Laboratories' Board convened an EGM for May 12, 2026 to regularize Ms. Khushbu Kachhawa as Non‑Executive Independent Woman Director; NSDL appointed for e‑voting, Ms. Sweety Kapoor as scrutinizer; e‑voting May 8–11 (cut‑off May 1).
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
246.00 | 267 Cr | 40.93 | 3.68 | 0.00 | 0.00 | 0.00 | 2.46 | ||
355.00 | 255 Cr | 55.73 | 12.77 | 0.00 | 15.67 | 18.38 | 8.59 | ||
50.73 | 255 Cr | 36.40 | 2.09 | 0.00 | 4.78 | 5.68 | 4.50 | ||
10.45 | 253 Cr | 13.73 | 1.18 | 0.00 | 7.77 | 8.53 | 5.49 | ||
28.75 | 247 Cr | 21.14 | 1.67 | 0.00 | 10.60 | 10.22 | 4.24 | ||
84.65 | 240 Cr | 79.86 | 1.66 | 0.00 | 2.41 | 5.22 | 1.17 | ||
12.17 | 240 Cr | -0.67 | 0.34 | 0.00 | -18.17 | -14.48 | -19.57 | ||
| Median: 7 Co. | — | 50.73 | 253 Cr | 36.40 | 1.67 | 0.00 | 4.78 | 5.68 | 4.24 |
